Core Viewpoint - Dynavax Technologies (DVAX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [4][6]. - For the fiscal year ending December 2024, Dynavax is expected to earn $0.20 per share, reflecting a 500% increase from the previous year's reported figure [8]. - Over the past three months, the Zacks Consensus Estimate for Dynavax has risen by 19.8%, indicating a positive trend in earnings expectations [8]. Institutional Investor Influence - Institutional investors play a role in stock price movements by adjusting their valuations based on earnings estimates, leading to buying or selling actions that affect stock prices [4][5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade of Dynavax to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $30 million contract with U.S. Department of Defense to advance plague vaccine program Cash, cash equivalents and marketable securities were approximately $714 million as of December 31, 2024EMERYVILLE, Calif., Jan. 13, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharm ...

Shares of Dynavax Technologies (DVAX) have gained 7.2% over the past four weeks to close the last trading session at $12.66, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $24.50 indicates a potential upside of 93.5%.The mean estimate comprises four short-term price targets with a standard deviation of $6.61. While the lowest estimate of $15 indicates an 18.5% increase from the ...

EMERYVILLE, Calif., Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. ET.The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/ev ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .We are circling back to Dynavax Technologies Corporation ( NASDAQ: DVAX ) today. The stock has moved up sharply since I last covered it in early September. There are some key facto ...

Investors might want to bet on Dynavax Technologies (DVAX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

Dynavax Technologies (DVAX) closed the last trading session at $13.01, gaining 24.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.50 indicates an 88.3% upside potential.The average comprises four short-term price targets ranging from a low of $15 to a high of $29, with a standard deviation of $6.61. While the lowest estimate indicates an increase of 15.3% from the current pr ...

EMERYVILLE, Calif., Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock. Dynavax executed the ASR as part of the $200 million share repurchase program authorized by its Board of Directors in ...

Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Jon Miller - Evercore Ernie Rodriguez - TD Cowen Paul Choi - Goldman Sachs Roy Buchanan - Citizen ...

| --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | Q3 2024 Financial Results | | | | | | Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases | | | | | | | | | | | | November 2024 Nasdaq: DVAX | | | | | Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-l ...